Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent
"We recently reported completion of enrollment in the third and final dose level of the dose optimization part of the trial. Results emerging from the third dose level support the data observed with the previous two cohorts, where we observed a protective effect of ALRN-6924 for severe anemia and severe thrombocytopenia when compared to historical rates of those toxicities in SCLC patients treated with topotecan,” said Dr. Manuel Aivado, President and CEO of
The Phase 1b study is designed to identify a dose and a schedule of ALRN-6924 administration to reduce chemotherapy toxicities such as severe anemia and thrombocytopenia, and other toxicities resulting from topotecan. ALRN-6924 is administered 24 hours (in the dose optimization part) or six hours (in the schedule optimization part) before each dose of topotecan, which is administered daily on days 1 through 5 of every 21-day treatment cycle.
Aileron currently plans to report interim results for the dose optimization part of the trial in
The Company continues to enroll patients into its chemoprotection trial while carefully monitoring the effect of the coronavirus pandemic on its clinical trial sites and the healthcare system, which may impact the timing of these planned data announcements.
About ALRN-6924
ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor that is currently being evaluated in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a chemoprotective agent to protect against chemotherapy-related toxicities.
About Aileron
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides. The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in drug candidates like ALRN-6924. Our current focus is to improve the standard of care for patients with cancer by developing safe and effective therapies that leverage our proprietary peptide platform. For more information, visit www.aileronrx.com, and for more information about our clinical trials please visit www.clinicaltrials.gov.
Forward-Looking Statements
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the
Investor Contacts:
617-995-0900
rwanstall@aileronrx.com
617-430-7578
hans@lifesciadvisors.com
Source: Aileron Therapeutics, Inc.